~$400m (£300m) · Growth/Late · Healthtech · Cambridge, UK
Cambridge-based CMR Surgical has agreed an approximately $400m (£300m) preferred-equity investment from Stryker to support further development and global commercialisation of its Versius surgical-robotics portfolio. The transaction is subject to regulatory approvals and customary closing conditions. Alongside the investment, Stryker will receive an exclusive option to acquire all remaining CMR equity and will become the exclusive US sales agent for Versius; CMR will continue leading product development and commercialisation outside the United States.
Capital and distribution arrive together
Versius Plus is a modular robot for minimally invasive soft-tissue surgery. Its independent bedside units can be arranged around an existing operating table and moved between rooms, while an open surgeon console keeps the operator in contact with the wider theatre team. The design targets hospitals that want to add robotic procedures without dedicating every case to one fixed room or a permanently installed system.
CMR entered the alliance with commercial and regulatory groundwork already in place. The company says its platforms have supported more than 40,000 procedures outside the US, and Versius Plus has FDA 510(k) clearance for cholecystectomy in adult patients. CMR has also submitted a further US application for benign gynaecological procedures, but that indication remains under review rather than cleared.
The financing therefore does more than extend CMR’s cash runway. Stryker brings hospital relationships, US sales infrastructure and experience commercialising medical technology. For CMR, that can shorten the route from regulatory clearance to hospital evaluation, surgeon training and recurring use. For Stryker, the preferred-equity position creates an entry into soft-tissue robotics without immediately buying the entire company.
The option changes the strategic horizon
The exclusive acquisition option is consequential, but it is not a completed sale. CMR remains an independent private company, and the current investment itself still has to close. That distinction matters because the next operating phase will determine the value of the option: Stryker needs Versius to convert its regulatory position and global procedure base into durable US adoption, while CMR needs a large commercial partner without losing momentum in markets it continues to manage directly.
Hospital adoption depends on more than placing hardware. Each programme needs trained surgical teams, enough suitable procedures to build utilisation, service support and evidence that the system fits existing operating-room economics. Versius’s modular format may make deployment more flexible, but repeatable use across hospitals and procedures is the commercial test.
The alliance aligns funding, distribution and a possible ownership outcome around that test. Its next milestones are the transaction closing, the US commercial rollout and any additional FDA indications. Until those happen, the $400m commitment should be read as backing for a defined expansion plan, not proof that the planned scale has already been achieved.
